169 related articles for article (PubMed ID: 38698123)
21. Optimization, characterization, and follicular targeting assessment of tretinoin and bicalutamide loaded niosomes.
Ghasemiyeh P; Moradishooli F; Daneshamouz S; Heidari R; Niroumand U; Mohammadi-Samani S
Sci Rep; 2023 Nov; 13(1):20023. PubMed ID: 37973805
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the in vivo leishmanicidal activity of amphotericin B emulgel: An alternative for the treatment of skin leishmaniasis.
Pinheiro IM; Carvalho IP; de Carvalho CE; Brito LM; da Silva AB; Conde Júnior AM; de Carvalho FA; Carvalho AL
Exp Parasitol; 2016 May; 164():49-55. PubMed ID: 26902606
[TBL] [Abstract][Full Text] [Related]
23. Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight.
Jamshaid H; Din FU; Khan GM
J Nanobiotechnology; 2021 Apr; 19(1):106. PubMed ID: 33858436
[TBL] [Abstract][Full Text] [Related]
24. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis.
Yardley V; Croft SL
Int J Antimicrob Agents; 2000 Feb; 13(4):243-8. PubMed ID: 10755238
[TBL] [Abstract][Full Text] [Related]
25. In vitro and in vivo anti-parasitic activity of biogenic antimony sulfide nanoparticles on Leishmania major (MRHO/IR/75/ER).
Mohtasebi S; Mohebali M; Elikaee S; Akhoundi B; Foroushani AR; Teimouri A; Yarizadeh H
Parasitol Res; 2019 Sep; 118(9):2669-2678. PubMed ID: 31278518
[TBL] [Abstract][Full Text] [Related]
26. Preparation and evaluation of niosomes containing autoclaved Leishmania major: a preliminary study.
Pardakhty A; Shakibaie M; Daneshvar H; Khamesipour A; Mohammadi-Khorsand T; Forootanfar H
J Microencapsul; 2012; 29(3):219-24. PubMed ID: 22150018
[TBL] [Abstract][Full Text] [Related]
27. In vitro and in vivo anti-parasitic activity of curcumin nanoemulsion on Leishmania major (MRHO/IR/75/ER).
Sahebi K; Shahsavani F; Mehravar F; Hatam G; Alimi R; Radfar A; Bahreini MS; Pouryousef A; Teimouri A
BMC Complement Med Ther; 2024 Jun; 24(1):238. PubMed ID: 38890586
[TBL] [Abstract][Full Text] [Related]
28. Nano-elastic liposomes as multidrug carrier of sodium stibogluconate and ketoconazole: A potential new approach for the topical treatment of cutaneous Leishmaniasis.
Dar MJ; Khalid S; Varikuti S; Satoskar AR; Khan GM
Eur J Pharm Sci; 2020 Mar; 145():105256. PubMed ID: 32032778
[TBL] [Abstract][Full Text] [Related]
29. Liposomal formulations in the pharmacological treatment of leishmaniasis: a review.
Ortega V; Giorgio S; de Paula E
J Liposome Res; 2017 Sep; 27(3):234-248. PubMed ID: 28874072
[TBL] [Abstract][Full Text] [Related]
30. Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis.
Jaafari MR; Hatamipour M; Alavizadeh SH; Abbasi A; Saberi Z; Rafati S; Taslimi Y; Mohammadi AM; Khamesipour A
Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():156-165. PubMed ID: 31582344
[TBL] [Abstract][Full Text] [Related]
31. Nanoparticles Loaded with a New Thiourea Derivative: Development and
Meireles PW; de Souza DPB; Rezende MG; Borsodi MPG; de Oliveira DE; da Silva LCRP; de Souza AMT; Viana GM; Rodrigues CR; do Carmo FA; de Sousa VP; Rossi-Bergmann B; Cabral LM
Curr Drug Deliv; 2020; 17(8):694-702. PubMed ID: 32621717
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of lapachol on treatment of cutaneous and visceral leishmaniasis.
Araújo IAC; de Paula RC; Alves CL; Faria KF; Oliveira MM; Mendes GG; Dias EMFA; Ribeiro RR; Oliveira AB; Silva SMD
Exp Parasitol; 2019 Apr; 199():67-73. PubMed ID: 30797783
[TBL] [Abstract][Full Text] [Related]
33. Evaluating the Effect of Cinnarizine on Promastigotes and Amastigotes forms of Leishmania major.
Sarouey LA; Rahimi-Moghaddam P; Tabatabaie F; Khanaliha K
Infect Disord Drug Targets; 2020; 20(4):550-555. PubMed ID: 30421686
[TBL] [Abstract][Full Text] [Related]
34. Poloxamer 407 (Pluronic(®) F127)-based polymeric micelles for amphotericin B: In vitro biological activity, toxicity and in vivo therapeutic efficacy against murine tegumentary leishmaniasis.
Mendonça DV; Lage LM; Lage DP; Chávez-Fumagalli MA; Ludolf F; Roatt BM; Menezes-Souza D; Faraco AA; Castilho RO; Tavares CA; Barichello JM; Duarte MC; Coelho EA
Exp Parasitol; 2016 Oct; 169():34-42. PubMed ID: 27427166
[TBL] [Abstract][Full Text] [Related]
35. In Vitro Determination of Antileshmanial Activities of Benzimidazolium Derivatives on L. major Promastigotes and Amastigotes.
Kelleci K; Gölebatmaz E
Acta Parasitol; 2023 Mar; 68(1):51-55. PubMed ID: 36348181
[TBL] [Abstract][Full Text] [Related]
36. Anti-Leishmanial Activity (In Vitro and In Vivo) of Allicin and Allicin Cream Using Leishmania major (Sub-strain Zymowme LON4) and Balb/c Mice.
Metwally DM; Al-Olayan EM; El-Khadragy MF; Alkathiri B
PLoS One; 2016; 11(8):e0161296. PubMed ID: 27537199
[TBL] [Abstract][Full Text] [Related]
37. In Vitro and In Vivo Antileishmanial Activity of Thioridazine.
Sifontes-Rodríguez S; Mollineda-Diogo N; Monzote-Fidalgo L; Escalona-Montaño AR; Escario García-Trevijano JA; Aguirre-García MM; Meneses-Marcel A
Acta Parasitol; 2024 Mar; 69(1):324-331. PubMed ID: 38070122
[TBL] [Abstract][Full Text] [Related]
38. The therapeutic effect of larval saliva and hemolymph of Lucilia sericata on the treatment of Leishmania major lesion in BALB/c mice946.
Rahimi S; Rafinejad J; Akhavan AA; Ahmadkhaniha R; Bakhtiyari M; Khamesipour A; Akbarzadeh K
Parasit Vectors; 2023 Feb; 16(1):72. PubMed ID: 36797798
[TBL] [Abstract][Full Text] [Related]
39. Use of topical liposomes containing meglumine antimoniate (Glucantime) for the treatment of L. major lesion in BALB/c mice.
Kalat SA; Khamesipour A; Bavarsad N; Fallah M; Khashayarmanesh Z; Feizi E; Neghabi K; Abbasi A; Jaafari MR
Exp Parasitol; 2014 Aug; 143():5-10. PubMed ID: 24780938
[TBL] [Abstract][Full Text] [Related]
40. Development, characterization, and anti-leishmanial activity of topical amphotericin B nanoemulsions.
Dos Santos Matos AP; Lopes DCDXP; Peixoto MLH; da Silva Cardoso V; Vermelho AB; Santos-Oliveira R; Viçosa AL; Holandino C; Ricci-Júnior E
Drug Deliv Transl Res; 2020 Dec; 10(6):1552-1570. PubMed ID: 32676952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
